I think people still don't appreciate the significance of 100 k project
in 100 k bacterias project they said going to sequensce at least 1000 microorganism, but final aim is 100,000 microorganism,
hence, if it $100 k per bacterial genome then minimal revenew $100 mln
and final revenue $10 bln,
if they do it in 2-3 years, then thats revenue $3-5 bln per year
and if you compare that to ILMN, which got annual revenue only about 1 bln and market cap 6 bln
then PACB market cap could be at least as high as ILMN ,
or as highs as 3-5 times of that.
corresponding to share price $100 and
if you approximate 5 times of ILMN would give share price $500
no wonder CEO and CFO buying stock and agreed to cut salary to $1
Sentiment: Strong Buy
This one is an Idiot for sure
while I agree that this company has some major potential... that's shooting pretty high my friend.
let's see $5 & $10 before we worry about $100 and $500... o'kay?
a few years back TASR went from $1 to $100, this could be another 100 bagger